We have entered a new era in understanding degenerative aortic stenosis in elderly patients. With the aging of the US population and the progressive decrease in coronary heart disease prevalence in the past 50 years, aortic stenosis has become a major cardiac concern. New perspectives of the dis- Because AS plays such a prominent role in cardiovascular care, there is a renewed interest in several aspects of the disease, including understanding the pathophysiologic processes, predicting adverse cardiac events accurately, diagnosing severe disease, and indicating cardiac surgical procedures. We are in a new era in which the timing of a surgical procedure is determined not just by the patient's symptoms, but also by the severity of the valve narrowing and the response of the left ventricle to valve stenosis.
development of aortic calcification. It has been suggested that the reason management of lipids did not demonstrate a beneficial effect is that the frequency of this risk allele is a low 5 or 6 per 100 persons. 7 Valvular calcification is also related to factors such as osteoporosis and renal failure. The evidence in favor of bisphosphonates in the management of aortic calcification is scant. 4 Oral calcium supplements have been suspected to accelerate disease pro gression, but this possibility has not been confirmed. Inflammation plays a role in the early phases of AS. 3 Traditional cardiac risk factors (eg, smoking, hypertension, obesity), metabolic syndrome, and diabetes lead to incorporation of low-density lipoprotein cholesterol and highly cytotoxic lipoprotein(a) particles into the valve.
The result is aortic sclerosis. It is unclear why a small percentage of patients with aortic sclerosis will undergo an accelerated process of valve leaflet calcification.
Logically, it would seem that management of these risk factors would reduce the progression of aortic valve disease. However, a large randomized controlled trial 5 showed no benefit to lipid lowering with a statin agent.
A recent, large international study of genome-wide risks for AS 6 identified a single nucleotide polymorphism that established lipoprotein(a) as a causative factor in the
KEY POINTS
Improved understanding of the pathophysiologic process of aortic stenosis has ushered in a new era in which disease severity is considered in terms of systemic conditions and the ventricular response to stenosis instead of just in terms of the aortic valve surface area.
Traditional cardiac risk factors are part of the predisposing conditions that lead to aortic sclerosis. A small percentage of these patients will progress to calcific aortic stenosis.
Presently, the guidelines for the treatment of patients with aortic stenosis recommend surgical treatment for only symptomatic patients. Although there is clinical evidence that many asymptomatic patients will benefit from surgical treatment, the guidelines have not yet caught up to that evidence.
If there is doubt about whether the patient is truly asymptomatic, exercise stress testing can be of benefit.
Longitudinal shortening, measured by excursion of the mitral valve annulus or by strain imaging, is useful in detecting left ventricular systolic dysfunction in patients with normal left ventricular ejection fraction. It has long been recognized that severe AS may occur in the setting of LV systolic dysfunction. In that situation, LV dysfunction renders the LV chamber weak, and it cannot generate high flow across the valve to produce a high peak systolic velocity or a high mean valve gradient. Echocardiographers estimate the aortic valve area using the continuity equation, which uses the LV outflow tract diameter and the flow velocity at that to severe, symptomatic AS. 3 There is considerable variation in the degree and pattern of LV hypertrophy. The progression from hypertrophy to heart failure involves myocyte-programmed cell death (apoptosis) and fibrosis.
In particular, fibrosis involves the subendocardial fibers, which are oriented longitudinally in the LV.
Bedside Approach
There are 3 cardinal symptoms of AS: chest discomfort, syncope, and dyspnea (or other symptoms of heart failure). In most patients, however, AS is identified well before patients have symptoms because of its characteristic heart murmur. By convention, physicians are accustomed to describing a murmur by its intensity (eg, grade II systolic murmur). In this context, it is helpful to recall the other characteristics of a heart murmur: pitch, quality, timing, configuration, and location. The murmur of severe AS can be mimicked by the sound of vigorously clearing your throat. It is harsh, rasping, and crescendodecrescendo. In severe AS, the murmur peaks in the last half of the systole, and the second heart sound is muffled.
Other bedside findings of AS such as delayed carotid upstroke are relegated to severe disease; therefore, it would be unusual that these symptoms alone would lead to the diagnosis. 
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and low valve gradient. 13 Approximately 31% of patients with severe AS had this form. These patients had the best prognosis with a 2-year cardiac event-free rate of 83%.
They had preserved longitudinal myocardial function and lower levels of brain natriuretic peptide (BNP).
The form in which the patient had low flow across the valve and high valve gradient accounted for 10% of patients. 13 These patients had a decrease in cardiac output manifested by a stroke volume index of less than 35 mL/ m 2 in spite of a normal LV ejection fraction. They had a decrease in longitudinal contraction of the ventricle and very elevated levels of BNP.
In the least common form of severe asymptomatic AS, the patient had low flow across the valve and low valve gradient. 13 This form accounted for 7% of asymptomatic patients with severe AS. In these patients, the In the second most common form of severe asymptomatic AS, the patient had normal flow across the valve 
EVIDENCE-BASED CLINICAL REVIEW
The It is important for physicians to determine if a patient with AS is truly asymptomatic. Because AS is typically found in elderly individuals, comorbid conditions may prevent a determination of exertional limitations. For example, the natural decline in activity levels that occurs with age may mask disease progression. In addition, patients may subconsciously limit their activities. One way physicians can determine if symptoms are being masked is to perform exercise stress testing. 8 The patient is considered to be asymptomatic if the exercise stress test shows a normal exercise duration, a normal blood pressure response to stress, and no evidence of exerciseinduced ventricular arrhythmias. The ST segment response to stress is not useful, and nuclear imaging is not needed. Because severe AS is historically considered to be a contraindication to exercise stress testing, the primary care physician is likely to defer the request for this test to the clinical cardiologist, who will perform the test in a setting where there is considerable experience with exercise stress testing.
Account for Body Size
The body surface area determines the cardiac output requirements. Therefore, AS severity may be overestimated in patients with small body surface areas and underestimated in patients with large body surface areas.
To accurately determine AS severity, physicians should divide the valve area by the body surface area to generate the valve area index. In this situation, the definition of
The aortic valve impedance is superior to aortic valve gradient and estimated valve area in predicting clinical outcomes.
Assess LV Geometry
The pattern of LV hypertrophy in response to AS is heterogeneous. There may be concentric remodeling, con- Table 2) . 14, 15 Further, patients with an abnormally high Z va do better with surgical intervention than with medical management, even if they are asymptomatic. If the patient with severe AS has any of the cardinal symptoms of angina, syncope, or heart failure, the guidelines are clear in the recommendation that the patient will benefit from aortic valve replacement, if clinically appropriate for his or her overall health status. If the patient has severe AS but is asymptomatic, there is evidence that many of these patients will do better with surgical treatment, but the guidelines have not caught up to this evidence base. In these cases, the physician or general cardiologist may choose to have the decision for a surgical procedure validated by a medical center with a structural heart disease program. These centers are likely to have programs for percutaneous valve replacement, a procedure that has been applied with increasing success in an expanding number of patient settings.
Conclusion
The management of severe AS calls for a coordinated approach that includes the primary care physician, the cardiologist, and the specialist who performs aortic valve replacement. New methods of management involve an position. This simple measurement can be performed in any echocardiography laboratory.
Identify Myocardial Damage
There are 2 markers of myocardial damage: fibrosis and elevated BNP levels. Fibrosis is easily identified by cardiac magnetic resonance imaging. 21 However, the cost of this procedure makes it prohibitive for screening purposes.
Brain natriuretic peptide is better than the usual parameters in terms of predicting myocardial damage and the subsequent clinical course for patients with AS. It also reflects the concomitant presence of coronary artery disease or cardiomyopathy. Most importantly, it reflects the total burden of disease on the left ventricle. 13 It varies by age and sex, and it should be measured routinely. However, unless the result is unequivocal (>500 µg/dL), the other variables described previously need to be considered with the BNP value as part of the definitive approach.
Summary
The initial diagnosis of AS is usually established by the primary care physician on a clinical basis. The next step is to stage the disease in terms of aortic valve stenosis severity, in terms of the response of the left ventricle to the stenosis burden, and in terms of systemic issues.
These systemic issues include those conditions directly related to the pathophysiologic process of valve stenosis and those comorbid conditions that would affect decision making, such as cognitive impairment, chronic obstructive lung disease, and limiting degenerative joint disease.
Because of the advanced age of many of these patients, the appropriateness of a cardiac surgical procedure for a patient with AS should be determined by the primary care team, the cardiologist, and the cardiac surgeon working together.
The new classification of severe AS in terms of high or low flow and high or low valve gradient is a useful way to further categorize patients in terms that have direct relevance to prognosis and management decisions.
If there is concern about whether the patient is truly asymptomatic, an exercise stress test can be useful.
TAKE-HOME POINTS
The primary care physician will usually establish the diagnosis of aortic stenosis at physical examination before the patient becomes symptomatic.
Guidelines for aortic stenosis recommend surgical treatment when the patient becomes symptomatic. The symptoms are chest discomfort, syncope, and dyspnea.
The primary care physician should arrange cardiac evaluation for patients who appear to have moderate or severe stenosis before they develop symptoms.
The left ventricular ejection fraction may be a misleading measurement of left ventricular systolic function in severe aortic stenosis. Brain natriuretic peptide should be measured routinely.
The final decision about the appropriateness of surgical treatment in patients with aortic stenosis will require the input of the primary care physician because of the advanced age of these patients and their multiple comorbidities. 
